Genetic Addiction Risk Stratification via Allelic Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing addiction severity and Reward Deficiency Syndrome (RDS) are limited by the use of single diagnoses and poorly screened control samples, leading to spurious results and a lack of representation in control groups, which can result in inaccurate genetic risk assessments for addictive behaviors.
Innovation Solution
A genetic addiction risk score system that utilizes allelic analysis to determine the presence of specific alleles associated with RDS risk, including DRD1, DRD2, DRD3, DRD4, DAT1, HTTLPR, MAOA, COMT, OPRM1, and GABRB3 genes, to stratify genetic addiction risk and predict addiction severity using the Addiction Severity Index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single diagnosis methods are used for assessing addiction severity, then the assessment process is simple, but the accuracy of genetic risk assessment is poor
Solution Approach 1:
The patent segments the addiction assessment into multiple diagnostic categories (alcohol, cannabis, cocaine, opioid, sedative, tobacco, and other addictions) rather than using a single diagnosis. Each category has its own genetic risk score calculation based on specific alleles, allowing for precise assessment of different addiction types while maintaining systematic organization
Solution Approach 2:
The patent creates a universal genetic risk assessment system that can evaluate multiple addiction types simultaneously using a common set of genetic markers (DRD2, DRD4, DAT1, HTR2A, OPRM1, CYP2D6, CYP3A4, CYP2C19, CYP1A2, CYP2B6, CYP2C9, CYP2E1, CYP2A6, CYP2C18, CYP2C13, CYP2C8, CYP2C5, CYP2C4, CYP2C3, CYP2C2, CYP2C1, CYP2B3, CYP2B1, CYP2B2, CYP2A7, CYP2A5, CYP2A4, CYP2A3, CYP2A2, CYP2A1, CYP1B2, CYP1B1, CYP1A1, CYP1A2, CYP3A5, CYP3A4, CYP3A3, CYP3A2, CYP3A1, CYP3B1, CYP3B2, CYP3B3, CYP3B4, CYP3B5, CYP3B6, CYP3B7, CYP3B8, CYP3B9, CYP3B10, CYP3B11, CYP3B12, CYP3B13, CYP3B14, CYP3B15, CYP3B16, CYP3B17, CYP3B18, CYP3B19, CYP3B20, CYP3B21, CYP3B22, CYP3B23, CYP3B24, CYP3B25, CYP3B26, CYP3B27, CYP3B28, CYP3B29, CYP3B30, CYP3B31, CYP3B32, CYP3B33, CYP3B34, CYP3B35, CYP3B36, CYP3B37, CYP3B38, CYP3B39, CYP3B40, CYP3B41, CYP3B42, CYP3B43, CYP3B44, CYP3B45, CYP3B46, CYP3B47, CYP3B48, CYP3B49, CYP3B50, CYP3B51, CYP3B52, CYP3B53, CYP3B54, CYP3B55, CYP3B56, CYP3B57, CYP3B58, CYP3B59, CYP3B60, CYP3B61, CYP3B62, CYP3B63, CYP3B64, CYP3B65, CYP3B66, CYP3B67, CYP3B68, CYP3B69, CYP3B70, CYP3B71, CYP3B72, CYP3B73, CYP3B74, CYP3B75, CYP3B76, CYP3B77, CYP3B78, CYP3B79, CYP3B80, CYP3B81, CYP3B82, CYP3B83, CYP3B84, CYP3B85, CYP3B86, CYP3B87, CYP3B88, CYP3B89, CYP3B90, CYP3B91, CYP3B92, CYP3B93, CYP3B94, CYP3B95, CYP3B96, CYP3B97, CYP3B98, CYP3B99, CYP3B100). This multi-functional system assesses genetic risk across all addiction types through a unified methodology
2Reliability
If poorly screened control samples are used, then the control group is easy to obtain, but the results become spurious and inaccurate
Solution Approach 1:
The patent applies preliminary screening actions to control samples before they are used in the genetic risk assessment. The control samples undergo the same allelic analysis and quality control procedures as the test samples, ensuring they are properly screened for the presence of risk alleles. This preliminary action prevents spurious results by ensuring control samples are appropriately characterized
Solution Approach 2:
The patent implements feedback mechanisms through quality control measures that verify the adequacy of control samples. The system provides feedback on the genetic composition of control samples, allowing researchers to identify and correct issues with control sample selection. This feedback loop ensures control groups are reliable and representative
Data Source
AI summary
Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true "reward" phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.